PARP1 and neoplasm: We employed 14 patient-derived tumor graft models pancreatic, lung, and prostate tumor graft models harboring HR mutations (BRCA1/2, CHK1/2, ATM/ATR, PALB2, PARP1/2, RAD51, FANCA/B) to compare LP-184’s potency with PARPi olaparib.